Maxim analyst Jason McCarthy initiated coverage of Alimera Sciences with a Buy rating and $10 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALIM:
- Alimera Sciences reports inducement grants under Nasdaq listing rule
- Alimera announces first patient randomized in radiation retinopathy trial
- Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network
- Alimera Sciences price target raised to $6 from $5 at H.C. Wainwright
- Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results